Overview

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia

Status:
Recruiting
Trial end date:
2027-12-02
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, multicenter, study to evaluate safety, tolerability and efficacy of SAR442501 in children from birth up to 12 years of age with Achondroplasia.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi